Endpoints News 生物医药· Elizabeth Cairns·· 13 小时前精选AI 评分76
FDA批准Regeneron siRNA疗法cemdisiran用于治疗重症肌无力
Regeneron enters neurology field as FDA approves siRNA for myasthenia gravis
AI 导读
Endpoints News报道,Regeneron的siRNA疗法cemdisiran获FDA批准用于治疗重症肌无力,是FDA在一周内批准的第二款该适应症新药。
推荐理由
FDA近期两次批准新药用于重症肌无力,cemdisiran作为第二款获批药物为罕见神经免疫疾病提供了新的siRNA治疗选择。
正文
Regeneron’s siRNA therapy cemdisiran has become the second new drug approved by the FDA for myasthenia gravis inside of a week.
Now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news